Interferon gamma
Interferon gamma (IFN-γ) is a type II interferon and a central cytokine of cell-mediated immunity.
Interferon gamma (IFN-γ) is a type II interferon and a central cytokine of cell-mediated immunity. It is produced predominantly by activated T-lymphocytes—especially T helper 1 (Th1) cells and CD8-positive T cells—and Natural killer cells. Unlike type I interferons, IFN-γ is encoded by interferon gamma (IFNG) and signals through a distinct receptor, the interferon gamma receptor (IFNGR), which activates Janus kinases and STAT1. STAT1-dependent transcription induces antimicrobial, antigen-presentation, and immune-regulatory programs in target cells.
IFN-γ promotes macrophage activation, enhances major histocompatibility complex expression, and supports immune responses against intracellular pathogens and malignant cells. Its activity is closely integrated with other cytokines, including interleukin 12, interleukin 2, Tumor necrosis factor-α (TNF-α)-α, Interleukin-1β (IL-1β), and Interleukin-6 (IL-6). Conversely, interleukin-4 (IL-4), interleukin 10, and transforming growth factor can counterbalance or regulate inflammatory responses. Excessive or dysregulated IFN-γ Signaling may contribute to tissue inflammation and immune-mediated disease, so its therapeutic use requires consideration of both antimicrobial benefit and inflammatory toxicity.
Recombinant human IFN-γ is used therapeutically in selected immune disorders, most notably to enhance host defense in chronic granulomatous disease and to treat severe malignant osteopetrosis in some clinical settings. Experimental applications include cancer immunotherapy, vaccine or immunization strategies, and engineered-cell approaches intended to increase local immune activation. Its effects are commonly assessed using methods such as flow cytometry, ELISA, western blotting, and measurements of serum cytokines, cell-mediated immunity, survival, or protection in animal models.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
9 papers study interferon gamma directly. Those 9 are one subject: Inflammatory Immune Signaling. Inflammatory immune signaling links IFN-γ to antigen presentation, T-cell killing, Th1 activation, cytokine recruitment and cancer-cell vulnerability. The work spans cancer, infection and inflammatory disease without a single therapeutic direction. No way of splitting those 9 scores better than chance. 2 new directions follow.
IFN-γ can reprogram tumor cells into autonomous and bystander tumoricidal effectors
The engineered tumor-cell model using IFNG overexpression found that tumor cells themselves, rather than immune effector cells, could acquire potent autonomous and bystander tumor-killing activity, suppressing neighboring wild-type tumors in vitro and in vivo. This departs from the set’s usual assignment of IFN-γ to immune-cell signaling or tumor sensitization: it makes IFN-γ a tool for converting malignant cells into cytotoxic effectors and suggests tumor-cell reprogramming as a distinct therapeutic strategy. 42139767May
IFN-γ is a mediator of persistent chemotherapy-induced bone-marrow and skeletal injury
The doxorubicin-treated murine leukemia model, supported by paired bone-marrow samples from patients with leukemia, found that increased CD8+ T-cell IFN-γ production contributed to long-term loss of arteriolar vasculature, impaired mesenchymal stromal-cell differentiation, skeletal damage, and reduced hematopoietic niche capacity; blocking IFN-γ partially restored these defects. This gives IFN-γ a pathogenic post-treatment role in remodeling and damaging the bone-marrow niche, beyond the set’s immune-activating, tumor-sensitizing, or infection-controlling roles. 42008378Apr
Recent Findings on Interferon gamma
IFN-γ Immune Regulation: IFN-γ strengthens antigen presentation and CD8+ T-cell killing by inducing MHC class I on medulloblastoma cells 42735303Sep. Intratumoral delivery, IFN-γ-engineered tumor cells, and monocytes with IFN-γ and IFN-α similarly support local tumoricidal activity and cell-mediated immune recruitment 42735303Sep42139767May42705863Sep. Cuproptotic tumor cells activate dendritic cells and prime CD8+ T cells, while T cell-derived IFN-γ increases FDX1 through the STAT1-IRF1 axis, supporting combinations with PD-L1 blockade 42624074Aug42330950Jun. IFN-γ-associated immunity also depends on context: Th1 cells control latent Cryptococcus neoformans infection, whereas CTLA-4 suppresses detrimental Th2 activation, and inflammatory signaling creates cytokine-specific cancer vulnerabilities 42484324Jul42496673Jul. Conversely, elevated IFN-γ accompanies idiopathic intracranial hypertension and drives chronic bone marrow niche dysfunction after doxorubicin, making inflammatory blockade a potential strategy for tissue protection 42214536May42008378Apr.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Last written: 2026-09-16 by GPT. Drafted by language models from published abstracts; not medical advice.